ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0802

Infection in Rheumatoid Arthritis Patients Treated with Golimumab
Abstract Number: 0992

Inflammatory Arthritis in HIV-Infected Humanized Mice
Abstract Number: 1505

Inflammatory Dendritic Cell and Th17 Polarization in Mouse Model of Lupus Nephritis
Abstract Number: 0920

Influence of Baseline Demographics on Improvements in Disease Activity Measures in Patients with Ankylosing Spondylitis Receiving Upadacitinib: A Post Hoc Subgroup Analysis
Abstract Number: 0192

Influence of Canakinumab Dosing on Efficacy and Safety of Long-term Treatment in Patients with Familial Mediterranean Fever – Interim Analysis of the RELIANCE Registry
Abstract Number: 0191

Influence of Canakinumab Dosing on Long-term Efficacy and Safety in Patients with Cryopyrin-associated Periodic Syndromes (CAPS) – 30-months Interim Analysis of the RELIANCE Registry
Abstract Number: 0470

Inhibition of Toll-Like Receptor 7 (TLR7) with the Potent and Selective Inhibitor of Human TLR7 and TLR8 BMS-986256 Provides Robust Efficacy in Murine Lupus Models, Reversing Established Disease
Abstract Number: 1439

Inhibitors of Endogenous Reverse Transcriptases Suppress in Vitro Type I Interferon Responses and in Vivo Antigen-specific T Cell Responses
Abstract Number: 1896

Initial Results from the Implementation of a National Hydroxychloroquine Safe Prescribing Dashboard Within the Veterans Health Administration
Abstract Number: 0995

Innate Immune Tolerance Attenuates Zymosan-Induced Arthritis, Inflammatory Gene Expression and Synovial Neutrophil Infiltration
Abstract Number: 0562

Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018
Abstract Number: 0895

Insight into Intraindividual Variability Across Neuropsychological Tests and Its Association with Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Abstract Number: 0546

Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis
Abstract Number: 1687

Integrated Laboratory Abnormality Profiles of Upadacitinib with up to 4.5 Years of Exposure in Patients with Rheumatoid Arthritis Treated in a Phase 3 Clinical Trial
Abstract Number: 1698

Integrated Safety Analysis Update for Filgotinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Receiving Treatment over a Median of 2.2 Years

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].